0001842952-21-000027.txt : 20211217 0001842952-21-000027.hdr.sgml : 20211217 20211217161834 ACCESSION NUMBER: 0001842952-21-000027 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211022 FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lehr Martin A. CENTRAL INDEX KEY: 0001861989 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40654 FILM NUMBER: 211501811 MAIL ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Context Therapeutics Inc. CENTRAL INDEX KEY: 0001842952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472566423 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 267-225-7416 MAIL ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: Context Therapeutics LLC DATE OF NAME CHANGE: 20210128 4/A 1 wf-form4a_163977590040895.xml FORM 4/A X0306 4/A 2021-10-22 2021-10-22 0 0001842952 Context Therapeutics Inc. CNTX 0001861989 Lehr Martin A. 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 1 1 0 0 Chief Executive Officer Common Stock 89583 D Common Stock 2021-10-22 4 O 0 52680 7.14 A 0 I Martin Lehr 2000 Trust Common Stock 2021-10-22 4 C 0 210715 A 210715 I Martin Lehr 2000 Trust Common Stock 2021-10-22 4 C 0 586475 A 797190 I Martin Lehr 2000 Trust Common Stock 2021-10-22 4 P 0 10000 5 A 807190 I Martin Lehr 2000 Trust Warrant (right to buy) 7.14 2021-10-22 4 O 0 52680 0 A 2020-12-20 2030-12-20 Common Stock 52680.0 0 I Martin Lehr 2000 Trust Series A Preferred Stock 2021-10-22 4 C 0 210715 D Common Stock 210715.0 7 I Martin Lehr 2000 Trust Series Seed Preferred Stock 2021-10-22 4 C 0 586475 D Common Stock 586475.0 1 I Martin Lehr 2000 Trust Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Fully vested. The attached amends and restates the Form 4 filed on October 25, 2021 in its entirety /s/ Alex Levit, Attorney-in-Fact 2021-12-17